

Legends to Supplementary Figures

Supplementary Figure 1. Overview of data preparation and analysis.

The flowchart is an extended version of Figure 1 which includes the data preparation steps performed for the ALSPAC and NFBC data prior to performing genome-wide association studies and subsequent analysis.

Supplementary Figure 2. Manhattan plot of a GWAS of self-reported glycosuria in the third trimester of pregnancy in ALSPAC

The line indicates a P value of 5×10^{-8} . The lead SNPs on chromosomes 9 and 16 are labelled

Supplementary Figure 3. QQ plot of GWAS of self-reported glycosuria in the third trimester in ALSPAC

QQ plot of test statistics shows inflation of associations at lower P values. The grey line indicates $y=x$. The genomic inflation factor (λ) is shown.

Supplementary Figure 4. Regional association plot of lead association on chromosome 9 (rs10991823) in ALSPAC GWAS.

P-values (on a $-\log_{10}$ scale) in ALSPAC are shown. Each SNP is coloured according to the degree of linkage disequilibrium (LD) with the lead SNP rs10991823 (shown as a purple diamond). LD values are from the 1000 Genomes (March 2012 release) European population (created using locuszoom.org build: hg19).

Supplementary Figure 5. Manhattan plot of a GWAS of midwife reported glycosuria in NFBC1986

The line indicates a P value of 5×10^{-8} . The lead SNPs on chromosomes 9 and 16 from the ALSPAC GWAS are labelled

Supplementary Figure 6. QQ plot of GWAS of midwife reported glycosuria in NFBC1986

QQ plot of test statistics shows inflation of associations at lower P values. The grey line indicates $y=x$. The genomic inflation factor (λ) is shown.

Supplementary Figure 7. Manhattan plot of the combined ALSPAC and NFBC1986 GWAS results

The line indicates a P value of 5×10^{-8} . The lead SNPs on chromosomes 9 and 16 from the ALSPAC GWAS are labelled

Supplementary Figure 8. QQ plot of the combined ALSPAC and NFBC1986 GWAS results

QQ plot of test statistics shows inflation of associations at lower P values. The grey line indicates $y=x$. The genomic inflation factor (λ) is shown.

Supplementary Figure 9. Direction of effect estimates from different GWAS' and effect estimates from ALSPAC GWAS

Scatter plot of effect estimates of associations from different GWAS' against effect estimates in a GWAS of glycosuria in ALSPAC. The blue line represents the Pearson correlation co-efficient. Effect estimates are the raw effects obtained from the GWAS of each trait; SNPs included are all those whose association in the respective GWAS reached genome wide significance ($p\text{-value} \leq 5 \times 10^{-8}$); eGFR: estimated glomerular filtration rate. The Pearson correlation coefficient and associated p-value is shown.

Legends to Supplementary Tables

Supplementary Table 1. SNPs reaching genome-wide significance ($P < 5 \times 10^{-8}$) for self-reported glycosuria in ALSPAC mothers

Results are ordered by P value. rsID: reported rsID; chr: chromosome; position: base position n; EA: effect allele; NEA: non-effect allele/other allele; EAF: effect allele frequency; P: reported p-value for EA; B: effect estimate; SE: standard error of the effect estimate; OR: odds ratio of the effect estimate;

CI_lower: lower 95% confidence interval for the OR; CI_upper: upper 95% confidence interval for the OR; info: information score.

Supplementary Table 2. Number of individuals with self-report glycosuria and reagent strip glycosuria, and Pearson correlation coefficient of the two measures of glycosuria

PCC gives the Pearson correlation coefficient and associated P value of self-reported glycosuria and reagent strip glycosuria in ALSPAC mothers with available genetic data.

Supplementary Table 3. SNPs reaching genome-wide significance ($P < 5 \times 10^{-8}$) for midwife reported glycosuria in NFBC1986 mothers

Results are ordered by P value. rsID: reported rsID; chr: chromosome; position: base position n; EA: effect allele; NEA: non-effect allele/other allele; EAF: effect allele frequency; P: reported p value for EA; B: effect estimate; SE: standard error of the effect estimate; OR: odds ratio of the effect estimate; CI_lower: lower 95% confidence interval for the OR; CI_upper: upper 95% confidence interval for the OR; info: information score.

Supplementary Table 4. SNPs reaching genome-wide significance ($P < 5 \times 10^{-8}$) in the combined GWAS results from ALSPAC and NFBC1986 mothers for self-reported and midwife reported glycosuria, respectively

Results are ordered by P value. rsID: reported rsID; chr: chromosome; position: base position; EA: effect allele; NEA: non-effect allele/other allele; EAF: weighted average of frequency for allele 1 across all studies; P: reported p value for EA; Zscore: the combined z-statistic for this marker; Weight: the sum of the individual study weights calculated as $4/(1/\text{cases} + 1/\text{controls})$; direction in ALSPAC and NFBC of the effect estimate respectively.

Supplementary Table 5. Validation of the doubling of offspring effect estimates in ALSPAC using logistic regression.

Trait: the glycosuria phenotype; Group: whether analysis was performed for offspring or maternal genotype; Note: additional information about the effect estimates present, doubled = the effect estimate and standard error were doubled; n: number of controls (i.e., those reporting no glycosuria); n_cases: number of cases (i.e., those reporting yes glycosuria); b = the logistic regression effect estimate; se: standard error of b; OR: odds ratio of the effect estimate; CI.lower/upper: OR lower and upper 95% confidence interval; P: p-value.

Supplementary Table 6. Overlap of SNPs reaching genome-wide significance in ALSPAC mothers with GWASs for HbA1c, fasting glucose, fasting insulin, type 2 diabetes, BMI, and estimated glomerular filtration rate

Where NA is present the SNP from the ALSPAC study was not found within the investigated GWAS. SNPs are ordered by lowest P value in the ALSPAC study, with the lead SNP on the first row. rsID: reported rsID; chr: chromosome; position: base position; EA: effect allele; NEA/OA: non-effect allele/other allele; EAF/MAF: effect allele frequency/minor allele frequency (the EAF/MAF was not available in the type 2 diabetes GWAS results obtained from DIAGRAM); B: effect estimate; SE: standard error of the effect estimate; P: reported p value for the EA. MAGIC: Meta-Analyses of Glucose and Insulin-related traits Consortium; DIAGRAM: DIAbetes Genetics Replication And Meta-analysis consortium; GIANT: Genetic Investigation of ANthropometric Traits consortium; T2D: type 2 diabetes; BMI: body mass index.

Supplementary Table 7. Genetic correlation of 832 traits in LD Hub with GWAS of self-reported glycosuria in ALSPAC mothers

Analysis was performed on 19/02/2019 with all 832 available traits in LD Hub. Data is presented for all traits and is ordered with the 43 pertinent traits first (in order of p-value) followed by all other traits (ordered by smallest to largest p-value). Where NA is present LD score regression analysis was not possible. Trait: the trait for which LD score regression with our GWAS of self-reported glycosuria in ALSPAC mothers was performed; PMID: PubMed identification number of the study the trait is from; Category: category trait falls within as defined by LD Hub; ethnicity: ethnicity of individuals tested in

the PMID study for the trait; note: note from LD Hub; rg: LD score regression genetic correlation estimate; SE: standard error of the rg; S: Z statistic; P: P value for the rg.

Supplementary Table 8. Ensembl Variant Effect Predictor output for the lead SNP on chromosome 16 (rs13337037) and SNPs in high LD ($R^2 \geq 0.8$)

We searched the lead SNP (rs13337037) with both rsID and chromosome:position:EA:NEA (16_31478711_A/G). The lead SNP identified in the ALSPAC GWAS is in bold at the top of the table. Uploaded variation: the input to Ensembl VEP either rsID or chromosome:position:EA; Location: in standard coordinate format (chr:start or chr:start-end); Allele: the variant allele used to calculate the consequence; Consequence: consequence type of this variant; Impact: the impact modifier for the consequence type; Symbol: the gene symbol; Gene: Ensembl stable ID of affected gene; Feature type: type of feature, currently one of Transcript, RegulatoryFeature, MotifFeature; Feature: Ensembl stable ID of feature; Biotype: Biotype of transcript or regulatory feature.

Supplementary Table 9. GTEx output for the lead SNP on chromosome 16 (rs13337037)

The table is order by P value. Gencode Id: Gencode identifier; Gene Symbol: gene symbol for Gencode Id; Variant Id: variant identifier of the searcher SNP Id in chromosome_position_NEA_EA format using build 37; SNP Id: searched rsID in GTEx; P: P value of eQTL; NES: normalized effect size; Tissue: tissue in which the rsID is associated with an eQTL.